Comparative Pharmacology
Head-to-head clinical analysis: TRULICITY versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRULICITY versus WEGOVY HD.
TRULICITY vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
1.5 mg subcutaneously once weekly, with or without food.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist